Physician profile
Ignacio Ortiz
NPI 1063865459
$1,784.45
in general payments reported to CMS, 2019-2025
19 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $91.78 · 2023: $469 · 2024: $396 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $451.55 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $284.89 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.57 | 2021-2025 | Jardiance |
| Amgen INC. | $140.52 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.41 | 2023-2025 | Lifevest |
| Scpharmaceuticals INC. | $132.07 | 2024-2025 | |
| Novo Nordisk INC | $109.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.73 | 2024-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $44.01 | 2025 | |
| Eisai INC. | $37.31 | 2021 | |
| Glaxosmithkline, LLC. | $35.88 | 2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $28.11 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $24.66 | 2023 | Injectafer |
| Baxter Healthcare | $24.11 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Biotronik INC. | $21.48 | 2023 | Edora 8 Dr-T, Biomonitor |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.61 | 2025 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.19 | 2021 | |
| Lilly USA, LLC | $18.25 | 2023 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $16.43 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.